Skip to content

AstraZeneca

Running coverage of AstraZeneca's pipeline readouts, approvals, deals and strategy shifts.

61 selectedRelated topicsDeals and financingClinical readoutsFDA

Latest picks

21–40 of 61
Oct 1Thu
  1. mp.weixin.qq.com68

    AstraZeneca Takes $2 Billion Stake of About 12% in Summit Therapeutics

    AstraZeneca will invest $2 billion in Summit Therapeutics by subscribing to convertible preferred shares, giving it about 12% of the company after conversion. Alongside the equity stake, announced September 28, the two firms signed a binding clinical collaboration combining Sone-Ve with Ivonescimab in GI tumors, plus a non-binding MOU to explore pairing Ivonescimab with more of AstraZeneca's ADC portfolio.

    Why it matters: Large equity stake plus clinical tie-ups between AstraZeneca and Summit Therapeutics signal possible pre-acquisition positioning.

  2. mp.weixin.qq.com68

    Dizhe Pharmaceutical Receives $600 Million Upfront from AstraZeneca, a Record for a Chinese Small Molecule

    Dizhe Pharmaceutical announced on the evening of September 29 that it has received the $600 million upfront payment from AstraZeneca, roughly 4 billion yuan. The sum sets a record for the largest upfront payment in an outbound licensing deal for a single Chinese small molecule drug. Founder Zhang Xiaolin has a relationship with AstraZeneca going back nearly twenty years.

    Why it matters: The payment sets a record upfront for a Chinese small molecule drug licensed abroad.

  3. mp.weixin.qq.com60

    AstraZeneca Takes $2 Billion Stake in Summit, Ivonescimab Overseas Rights Holder

    AstraZeneca invested $2 billion in convertible preferred shares of Summit, the holder of overseas rights to Akeso's PD-1/VEGF bispecific antibody ivonescimab, taking roughly a 12% stake. The deal, disclosed on September 28, 2026, gives AstraZeneca no rights to the drug itself but makes it the sponsor of clinical trials combining ivonescimab with its own ADC. Summit shares rose about 18% after hours and Akeso's Hong Kong shares gained more than 15% the next day.

    Why it matters: AstraZeneca's $2 billion stake links its ADC pipeline to ivonescimab without buying drug rights.

Sep 29Tue
  1. BioSpace52

    Summit snags $2B investment from AstraZeneca, clearing financial overhang

    AstraZeneca is investing $2 billion in Summit Therapeutics through a direct equity purchase of about 109,000 preferred shares, giving it roughly 12% of Summit's common shares at $18.36 per share, a 10% premium. The deal, expected to close within a week pending regulatory clearances, lifts Summit's cash to an estimated $2.5 billion and leaves it holding full rights to ivonescimab, the PD-1/VEGF bispecific, in its territories. The partners will also start trials pairing AstraZeneca's anti-CLDN18.2 ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers, while the FDA decides Summit's BLA for the NSCLC drug by Nov. 14.

    Why it matters: Large pharma is paying $2 billion for equity exposure to the PD-1/VEGF class without licensing ivonescimab.

Sep 17Thu
  1. mp.weixin.qq.com69

    NMPA Approves T-DXd Plus Pertuzumab for First-Line HER2-Positive Metastatic Breast Cancer

    China's NMPA approved on August 11, 2026 the combination of trastuzumab deruxtecan (T-DXd) with pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. The approval rests on the global DESTINY-Breast09 trial. The regimen challenges the long-standing escalation model in which patients start on trastuzumab plus pertuzumab with a taxane and switch to an ADC only after progression.

    Why it matters: First-line approval for T-DXd plus pertuzumab shifts a decade-old treatment sequence in HER2-positive metastatic breast cancer.

Sep 15Tue
  1. biocentury.com59

    AZ’s camizestrant miss narrows oral SERD treatment settings

    AstraZeneca's camizestrant missed its primary endpoint of progression-free survival in the Phase III SERENA-4 trial in first-line HER2-negative, estrogen receptor-positive breast cancer, where it was combined with the CDK4/6 inhibitor palbociclib. This is the second Phase III setback this year for oral SERDs in an early-line breast cancer setting, and both results suggest proving efficacy may require focusing on patients with ESR1 mutations.

    Why it matters: A second Phase III oral SERD failure narrows where the class can compete and points to ESR1-mutant selection.

Sep 14Mon
  1. mp.weixin.qq.com74

    Trastuzumab Deruxtecan Extends Median PFS to 14.3 Months as First-Line Therapy in HER2-Mutant Advanced NSCLC

    In the phase III DESTINY-Lung04 trial, first-line trastuzumab deruxtecan (Enhertu) gave a median progression-free survival of 14.3 months in patients with HER2-mutant advanced non-small cell lung cancer, versus 8.3 months with pembrolizumab plus chemotherapy. It is the first HER2-targeted therapy to show superiority over standard treatment in this setting.

    Why it matters: First HER2-targeted therapy to beat standard first-line care in HER2-mutant advanced NSCLC in phase III.

  2. mp.weixin.qq.com61

    AstraZeneca Oral SERD Camizestrant Misses PFS Primary Endpoint in Phase 3 SERENA-4 First-Line Breast Cancer Trial

    Camizestrant plus the CDK4/6 inhibitor palbociclib missed the primary endpoint of progression-free survival compared with anastrozole plus palbociclib in the phase 3 SERENA-4 trial, AstraZeneca announced on September 11. The randomized, double-blind study enrolled 1371 patients with ER-positive, HER2-negative advanced breast cancer receiving no prior systemic therapy for advanced disease, including 194 in mainland China, across 263 sites. The result weakens the case for the oral SERD as a first-line endocrine partner to palbociclib.

    Why it matters: Phase 3 miss for camizestrant in first-line ER-positive, HER2-negative advanced breast cancer.

  3. mp.weixin.qq.com68

    Enhertu Extends PFS in DESTINY-Lung04 but Early Overall Survival Signals 15% Higher Death Risk

    Enhertu posted strong progression-free survival in the DESTINY-Lung04 trial presented at WCLC 2026: median PFS of 14.3 months, 6 months longer than control, with a 37% reduction in risk of disease progression or death and an ORR of 70% versus 44.5%. Preliminary overall survival did not favor the drug: 115 deaths (50.7%) on Enhertu versus 98 (43.2%) on control, median OS 29.3 versus 33.1 months, a 15% higher risk of death.

    Why it matters: A widely used ADC shows a clear PFS gain in lung cancer while preliminary OS runs against it.

  4. mp.weixin.qq.com60

    First-in-human GPC3 armored CAR-T shows 91.7% disease control in advanced liver cancer, published in Nature

    A first-in-human trial of GPC3 armored CAR-T (C-CAR031, AZD7003), reported in Nature by a team at the First Affiliated Hospital of Zhejiang University School of Medicine, achieved a disease control rate of 91.7% in patients with advanced hepatocellular carcinoma who had failed multiple lines of therapy. The cells are engineered to resist the TGF-β-rich immunosuppressive microenvironment that exhausts infiltrating CAR-T cells in liver cancer. It provides clinical evidence for cell therapy in a solid tumor where CAR-T has not previously translated.

    Why it matters: First-in-human evidence that a TGF-β-armored CAR-T can work in advanced hepatocellular carcinoma.

Sep 12Sat
  1. statnews.com54

    STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial

    AstraZeneca's oral drug camizestrant, sold as Etcamah, failed to beat standard treatment in the pivotal SERENA-4 trial as first-line therapy for ER-positive, HER2-negative advanced breast cancer. The combination did not extend the time patients went before their cancer progressed. The miss limits expansion beyond the accelerated U.S. approval for tumors with a drug-resistance mutation, though testing continues in early-stage disease.

    Why it matters: Negative pivotal first-line result narrows the market for a newly approved breast cancer pill.

Sep 11Fri
  1. nature.com61

    Selective oestrogen receptor degrader class grows with new cancer approval

    The FDA has approved AstraZeneca's camizestrant (Etcamah), a selective oestrogen receptor degrader, as part of a combination therapy for a subset of breast cancer patients. The drug targets patients whose tumours have acquired resistance mutations to aromatase inhibitors. It expands the SERD class of therapies.

    Why it matters: FDA approval of a new SERD widens treatment options for aromatase inhibitor-resistant breast cancer.

Sep 10Thu
  1. mp.weixin.qq.com70

    FDA Grants Accelerated Approval to AstraZeneca's camizestrant Plus CDK4/6 Inhibitors for ESR1-Mutant Breast Cancer

    AstraZeneca's camizestrant, combined with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), received FDA accelerated approval on September 4 for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer who developed ESR1 mutations during aromatase inhibitor and CDK4/6 inhibitor treatment. The FDA also approved a companion diagnostic that detects emerging ESR1 resistance mutations in circulating tumor DNA. The approval rests on the pivotal Phase III SERENA-6 trial.

    Why it matters: FDA accelerated approval of AstraZeneca's camizestrant plus CDK4/6 inhibition for ESR1-mutant breast cancer, with a ctDNA companion diagnostic.

  2. mp.weixin.qq.com60

    Tozorakimab Shows Significant COPD Exacerbation Reduction in OBERON and TITANIA Trials

    Tozorakimab is the first biologic to show statistically and clinically meaningful improvement in reducing moderate-to-severe exacerbations in a broad COPD population that still exacerbates despite standard inhaled therapy, based on full positive results from the OBERON and TITANIA trials. Clinical benefit was seen across blood eosinophil levels. Full results were published in the New England Journal of Medicine and reported at the European Respiratory Society annual congress.

    Why it matters: First biologic to significantly reduce COPD exacerbations across eosinophil levels in two positive trials.

Sep 8Tue
  1. statnews.com64

    STAT+: AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies

    AstraZeneca's injectable drug tozorakimab reduced COPD exacerbations by about 30% across all patients over a year in a pair of Phase 3 trials, with data presented at the European Respiratory Society conference and published in the New England Journal of Medicine. The trials included participants not eligible for other new COPD drugs, potentially giving the company a market segment to itself, with analysts projecting billions in annual sales if approved.

    Why it matters: Phase 3 results position tozorakimab as a COPD option for patients ineligible for other new drugs.

  2. N Engl J Med63

    Tozorakimab to Prevent COPD Exacerbations.

    Add-on tozorakimab, an interleukin-33 inhibitor, cut the annualized rate of moderate or severe COPD exacerbations by roughly 30% in two replicate phase 3 trials, OBERON and TITANIA, with no eosinophil-count eligibility criteria. Among former smokers, rates fell from 1.90 to 1.34 events per year (rate ratio 0.71) in OBERON and from 2.07 to 1.37 (rate ratio 0.66) in TITANIA. It offers a biologic option for exacerbation prevention independent of eosinophil status.

    Why it matters: Phase 3 data show an IL-33 biologic reduces COPD exacerbations regardless of eosinophil count.

  3. mp.weixin.qq.com67

    FDA grants accelerated approval to AstraZeneca's camizestrant combinations for ESR1-mutant breast cancer

    The FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant) combined with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose ESR1 mutations were detected during aromatase inhibitor and CDK4/6 inhibitor therapy. The FDA also approved a companion diagnostic for detecting emerging ESR1 resistance mutations in ctDNA. The approval rests on positive results from the pivotal Phase III SERENA-6 study.

    Why it matters: Accelerated FDA approval of a new endocrine therapy option for ESR1-mutant advanced breast cancer matters to oncology prescribers.

Sep 5Sat
  1. FDA Press Releases59

    FDA Grants Accelerated Approval to a New Breast Cancer Treatment

    The FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant), an oral tablet, combined with a CDK4/6 inhibitor (abemaciclib, palbociclib or ribociclib) for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors show an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, detected by the FDA-authorized Guardant360 CDx companion diagnostic. In the pivotal trial, estimated median progression-free survival was 16 months versus 9.2 months for continuing an aromatase inhibitor plus a CDK4/6 inhibitor. The label carries a boxed warning for irregular heart rhythm, and confirmatory trials are required to verify clinical benefit.

    Why it matters: First FDA approval of a cancer therapy guided by ctDNA resistance-mutation detection before imaging shows progression.

Sep 2Wed
  1. mp.weixin.qq.com66

    Dizhe Medicine-AstraZeneca License for Sunvozertinib Takes Effect, $600 Million Upfront Due

    Dizhe Pharmaceutical (Dizhe Medicine) said its July 14, 2026 license agreement with AstraZeneca has taken effect, granting AstraZeneca exclusive worldwide rights to develop and commercialize Sunvozertinib (Shuwozhe). AstraZeneca plans to launch the drug in the US in the fourth quarter of this year. Dizhe receives a $600 million upfront payment, up to $400 million in clinical development milestones, up to $500 million in sales milestones, and tiered royalties on global sales from high single to low double digits.

    Why it matters: A $600 million upfront license deal with AstraZeneca takes effect and a US launch is set for Q4.

  2. vbdata.cn62

    Dizhe Files for Hong Kong Listing After AstraZeneca Sunvozertinib Deal With $600 Million Upfront

    Dizhe Pharmaceutical (Dizhe Pharmaceutical) has filed an H-share listing application with the Hong Kong Stock Exchange in August 2026, four years after raising about 2.1 billion yuan on the STAR Market. Concurrently, a global exclusive license with AstraZeneca for sunvozertinib (sunvozertinib, DZD9008), effective August 31, gives Dizhe a $600 million upfront payment, up to $400 million in development milestones and up to $500 million in sales milestones, plus tiered royalties; AstraZeneca will commercialize the EGFR exon20ins NSCLC drug in the US in Q4 2026. Dizhe posted 522 million yuan in revenue in H1 2026 and will channel proceeds into clinical development of golidocitinib, DZD6008 and birutinib (DZD8586).

    Why it matters: A record $600 million upfront for a Chinese small-molecule asset pairs with an A+H listing filing from a commercial-stage biotech.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org